Pfizer BioNTech BA.4/BA.5 booster against Covid-19 shows greater efficacy

Pfizer and BioNTech's Covid-19 booster revealed greater efficacy against the BA.4/BA.5 variants of the virus than their original shot in persons older than 55.

A month after administering a 30 microgram dose antibody titers against the BA.4/BA.5 variants jumped by 13.2-fold in comparison to their levels from before the booster, the results of a phase 2/3 clinical trial revealed.

Among adults between 18-55 years of age, titers were up 9.5 times.

Adults older than 55 who had been given the original vaccine only saw a 2.9-fold increase.

As of 1535 GMT, shares of Pfizer were up by 1.43% to $47.24 and those of BioNTech by 5.10% to $152.67.